The impact of low-dose busulfan on clonal dynamics in nonhuman primates

Blood

Volumn 104, Issue 5, 2004, Pages 1273-1280

  Kuramoto, Ken ^b   Follman, Dean ^b   Hematti, Peiman ^b   Sellers, Stephanie ^b   Laukkanen, Mikko O ^b   Seggewiss, Ruth ^b   Metzger, Mark E ^b   Krouse, Allen ^b   Donahue, Robert E ^b   Von Kalle, Christof ^b   Dunbar, Cynthia E ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD34 ANTIGEN; FIBRONECTIN; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RETROVIRUS VECTOR; STEM CELL FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE THERAPY; GRANULOPOIESIS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE CLONE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY;

EID: 4444302256     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2935     Document Type: Article

References (41)

1. Abkowitz JL, Fialkow PJ, Niebrugge DJ, Raskind WH, Adamson JW. Pancytopenia as a clonal disorder of a multipotent hematopoietic stem cell. J Clin Invest. 1984;73:258-261.
2. Abkowitz JL, Catlin SN, Guttorp P. Evidence that hematopoiesis may be a stochastic process in vivo. Nat Med. 1996;2:190-197.
3. Guenechea G, Gan OI, Dorrell C, Dick JE. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol. 2001;2:75-82.
4. Jordan CT, Lemischka IR. Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes Dev. 1990;4:220-232.
5. Lemischka IR, Jordan CT. The return of clonal marking sheds new light on human hematopoietic stem cells. Nat Immunol. 2001;2:11-12.
6. Schmidt M, Hoffmann G, Wissler M, et al. Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum Gene Ther. 2001;12:743-749.
7. Kim HJ, Tisdale JF, Wu T, et al. Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates. Blood. 2000;96:1-8.
8. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410-2413.
9. Morley A, Blake J. An animal model of chronic aplastic marrow failure. I. Late marrow failure after busulfan. Blood. 1974;44:49-56.
10. McManus PM, Weiss L. Busulfan-induced chronic bone marrow failure: changes in cortical bone, marrow stromal cells, and adherent cell colonies. Blood. 1984;64:1036-1041.
11. Molineux G, Testa NG, Massa G, Schofield R. An analysis of haemopoietic and microenvironmental populations of mouse bone marrow after treatment with busulphan. Biomed Pharmacother. 1986;40:215-220.
12. National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press, 1996.
13. Hematti P, Sellers SE, Agricola BA, et al. Retroviral transduction efficiency of G-CSF+SCF-mobilized peripheral blood CD34+ cells is superior to G-CSF or G-CSF+Flt3-L-mobilized cells in nonhuman primates. Blood. 2003;101:2199-2205.
14. Takatoku M, Sellers S, Agricola BA, et al. Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates. J Clin Invest. 2001;108:447-455.
15. Cassel A, Cottler-Fox M, Doren S, Dunbar CE. Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells. Exp Hematol. 1993;21:585-591.
16. Tisdale JF, Hanazono Y, Sellers SE, et al. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood. 1998;92:1131-1141.
17. Schmidt M, Zickler P, Hoffmann G, et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood. 2002;100:2737-2743.
18. Dunbar CE, Cottler-Fox M, O'Shaughnessy J, et al. Retrovirally-marked CD34-enriched peripheral blood and bone marrow and cells contribute to long-term engraftment after autologous transplantation. Blood. 1995;85:3048-3057.
19. Dunn CDR. The chemical and biological properties of busulfan. Exp Hematol. 1974;2:101-117.
20. Down JD, Ploemacher RE. Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs. Exp Hematol. 1993;21:913-921.
21. Down JD, Boudewijn A, Dillingh JH, Fox BW, Ploemacher RE. Relationships between ablation of distinct haematopoietic cell subsets and the development of donor bone marrow engraftment following recipient pretreatment with different alkylating drugs. Br J Cancer. 1994;70:611-616.
22. Hassan M. The role of busulfan in bone marrow transplantation. Med Oncol. 1999;16:166-176.
23. Botnick LE, Hannon EC, Hellman S. Limited proliferation of stem cells surviving alkylating agents. Nature. 1976;262:68-70.
24. Botnick LE, Hannon EC, Vigneulle R, Hellman S. Differential effects of cytotoxic agents on hematopoietic progenitors. Cancer Res. 1981;41:2338-2342.
25. Weatherall DJ, Galton DA, Kay HE. Busulphan and bone marrow depression. Br Med J. 1969;1:638.
26. Neben S, Hellman S, Montgomery M, et al. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol. 1993;21:156-162.
27. Abkowitz JL, Ott RM, Holly RD, Adamson JW. Clonal evolution following chemotherapy-induced stem cell depletion in cats heterozygous for glucose-6-phosphate dehydrogenase. Blood. 1988;71:1687-1692.
28. Abkowitz JL, Linenberger ML, Persik M, Newton MA, Guttorp P. Behavior of feline hematopoietic stem cells years after busulfan exposure. Blood. 1993;82:2096-2103.
29. Abkowitz JL, Taboada M, Shelton GH, et al. An X chromosome gene regulates hematopoietic stem cell kinetics. Proc Natl Acad Sci U S A. 1998;95:3862-3866.
30. Rao SS, Peters SO, Crittenden RB, et al. Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment. Exp Hematol. 1997;25:114-121.
31. Perez-Simon JA, Diez-Campelo M, Martino R, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood. 2003;102:1108-1113.
32. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410-2413.
33. Donahue RE, Dunbar CE. An update on the use of non-human primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells. Hum Gene Ther. 2001;12:607-617.
34. Fialkow PJ, Jacobsen RJ, Papayannopolov T. Chronic myelogenous leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977;63:125-130.
35. Abkowitz JL, Linenberger ML, Persik M, Newton MA, Guttorp P. Behavior of feline hematopoietic stem cells years after busulfan exposure. Blood. 1993;82:2096-2103.
36. Cheshier SH, Morrison SJ, Liao X, Weissman IL. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci U S A. 1999;96:3120-3125.
37. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985;65:1364-1372.
38. Miller JS, Arthur DC, Litz CE, et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood. 1994;83:3780-3786.
39. Rodjer S, Swolin B, Weinfeld A, Westin J. Cytogenetic abnormalities in acute leukemia complicating melphalan-treated multiple myeloma. Cancer Genet Cytogenet. 1990;48:67-73.
40. Kauppi MJ, Savolainen HA, Anttila VJ, Isomaki HA. Increased risk of leukaemia in patients with juvenile chronic arthritis treated with chlorambucil. Acta Paediatr. 1996;85:248-250.
41. Rosenthal NS, Farhi DC. Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. Am J Clin Pathol. 1996;106:676-679.